Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R,4R,4aR,7R,8aS)-4,7-dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol
-
(2R,4S,4aR,7R,8aS)-4,7-dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol
-
(S)-3-(4-hydroxy-3-methoxyphenyl)propane-1,2-diol-2-beta-D-(6'-O-galloyl) glucopyranoside
-
2,2,2-trifluoro-N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
-
2,2,2-trifluoro-N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
-
2-(2,6-dimethylhept-5-en-1-yl)-5,7-dimethyl-1,3-diazatricyclo[3.3.1.1(3,7)]decan-6-one
-
3,20-dioxopregn-4-en-21-yl 4-bromobenzene-1-sulfonate
-
3,4-dimethoxyphenol-1-beta-D-(6'-O-galloyl)glucopyranoside
-
3-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
3-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
3-((3,4,5-trimethoxybenzyl)oxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
3-((3-methoxybenzyl)oxy)-7,8,9,10-tetrahydro-6Hbenzo[c]chromen-6-one
-
3-(2-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
3-(4-hydroxy-3-methoxyphenyl)propane-1,2-diol 2-beta-D-(6'-O-galloyl)glucopyranoside
-
3-(benzyloxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
4,4'-(furan-2,5-diyl)di(benzene-1-carboximidamide)
-
4-methyl-7-((3,4,5-trimethoxybenzyl)oxy)-2H-chromen-2-one
-
6,6'-[(1R,2R,3S,4S)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-diyl]di(2H-pyran-2-one)
-
6-(3-aminopropyl)-8-hydroxy-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
7-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-4-methyl-2H-chromen-2-one
-
7-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-4-methyl-2H-chromen-2-one
-
7-((3,4,5-trimethoxybenzyl)oxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-((3-methoxybenzyl) oxy)-4-methyl-2H-chromen-2-one
-
7-((3-methoxybenzyl)oxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-(2-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-(benzyloxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
7-[[(1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methoxy]-2,3-dihydrobenzo[b]cyclopenta[d]pyran-4(1H)-one
-
methyl-3,4-dephostatin
a dephostatin derivative, structure-activity relationship analogues of this active compound that have a chemical substitution at a single position show a dramatic decrease in inhibition activity
N-(3,7-dimethyloct-6-en-1-yl)tricyclo[3.3.1.1(3,7)]decan-2-amine
-
N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
-
N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)benzamide
-
N-(5-((2R,4R,4aR,7R,8aS)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-1-carboxamide
-
N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
-
N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2yl)benzamide
-
N-(5-((2R,4S,4aR,7R,8aS)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-1-carboxamide
-
N2,N2-dibutyl-N-[8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-yl]glycinamide
-
NSC88915
a deoxycorticosterone derivative of progesterone coupled to methyl-p-toluene-sulfonate, structure-activity relationship analogues of this active compound that have a chemical substitution at a single position show a dramatic decrease in inhibition activity
(5Z)-5-(2,3,4-trihydroxybenzylidene)-1,3-thiazolidine-2,4-dithione
-
-
(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)carbamic acid
-
-
(RP)-adenosine 5'-(alpha-thio-beta,gamma-dichloromethylene)triphosphate
-
-
(RP)-adenosine 5'-(alpha-thio-beta,gamma-methylene)triphosphate
-
-
(SP)-adenosine 5'-(alpha-thio-beta,gamma-dichloromethylene)triphosphate
-
-
(SP)-adenosine 5'-(alpha-thio-beta,gamma-methylene)triphosphate
-
-
2,2,2-trifluoro-N-(8-(trifluoromethyl)benzo[f][1,2,3,4,5]pentathiepin-6-yl)acetamide
-
2-((6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino)acetic acid
-
-
2-(3-(dimethylamino)propoxy)-3-methoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
2-(3-(ethylamino)propoxy)-3-methoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
2-(3-aminopropoxy)-3-methoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
2-(dibutylamino)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
-
2-(piperidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
-
2-(pyrrolidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
-
2-mercaptoethanol
-
inactivation reversed by Zn2+
2-morpholino-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
-
3,20-dioxopregn-4-en-21-yl 4-bromobenzenesulfonate
-
-
3-(piperidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
-
3-(pyrrolidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
-
3-amino-6-(3-aminopropyl)-5,6-dihydro-9-methoxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline dihydrochloride
-
-
3-amino-6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
3-cyano-6,11-dihydro-5,11-dioxo-6-[3-(dimethylaminopropyl)-5H-indeno[1,2-c]isoquinoline]
-
-
3-iodo-9-methoxy-6-(3-(dimethylamino)propyl)-5H-indeno-[1,2-c]isoquinoline-5,11(6H)-dione
-
-
3-isobutyl-1-methyl xanthine
-
-
3-methoxy-6-(3-morpholinopropyl)-2-(3-(piperidin-1-yl)-propoxy)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
3-methoxy-6-(3-morpholinopropyl)-2-(3-(pyrrolidin-1-yl)-propoxy)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione
-
-
3-morpholino-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
-
4-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoic acid
-
-
5-[3-benzyloxyphenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4-(t-butyldimethylsilyloxy)-phenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4-benzyloxyphenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione
-
-
5-[4-pyridyl]-1,3,4-thiadiazole-2(3H)-thione
-
-
6,6'-[propane-1,3-diylbis(iminopropane-3,1-diyl)]bis(5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione)
-
-
6-(10-aminodecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(11-aminoundecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(12-aminododecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(2-aminoethyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-(1H-imidazol-1-yl)propyl)-8-methoxy-3-nitro-5Hindeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-3-(methylamino)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
6-(3-aminopropyl)-5,6-dihydro-9-methoxy-3-iodo-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
-
-
6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-7-methoxy-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(3-aminopropyl)-9-methoxy-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(4-aminobutyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(5-aminopentyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(6-aminohexyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(7-aminoheptyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(8-aminooctyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-(9-aminononyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
-
-
6-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoic acid
-
-
8-thioadenosine 5'-triphosphate
-
-
adenosine 5'-(gamma-thio-beta,gamma-methylene)triphosphate
-
-
ADP-ribose
-
competitive to diuridine tetraphosphate
alpha,beta-methylene-adenosine triphosphate
-
inhibition in decreasing order: alpha,beta-methyl-adenosine triphosphate, ATP, UTP, GTP, CTP
aminobenzopentathiepine
-
bis(1,3,4-oxadiazol-2-propyl)-5-thione
-
-
Citric acid
-
slight inhibition
CTP
-
inhibition in decreasing order: alpha,beta-methylene-adenosine triphosphate, ATP, UTP, GTP, CTP
cystine
-
slight inhibition
diphosphate
-
slight inhibition
ethyl 2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]acetate
-
-
methyl 2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetate
-
-
methyl 3-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate
-
-
methyl 4-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate
-
-
methyl 5-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate
-
-
methyl 6-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoate
-
-
N-(2-[1-[2-(2-methyl-1H-imidazol-1-yl)pyrimidin-4-yl]piperidin-4-yl]ethyl)sulfuric diamide
-
-
N-(2-[1-[6-(2-methyl-1H-imidazol-1-yl)pyrimidin-4-yl]piperidin-4-yl]ethyl)sulfuric diamide
-
-
N-phenyl-2-(piperidin-1-yl)acetamide
-
N-phenyl-2-(pyrrolidin-1-yl)acetamide
-
N-[2-(1-[6,7-dimethoxy-2-[(E)-2-(pyridin-3-yl)ethenyl]quinazolin-4-yl]piperidin-4-yl)ethyl]sulfuric diamide
-
-
N-[2-[1-(2-ethyl-6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
-
N-[2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
enzyme binding, structure modelling, overview
N-[2-[1-(6-chloroquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
-
N-[2-[1-(7-chloroquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
-
N-[2-[1-(7-methoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
-
N-[6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide
-
-
neomycin B
-
a aminoglycoside
NSC88915
-
a steroid inhibitor
nucleoside 5'-triphosphate
-
-
Reducing agents
-
inactivation reversed by Zn2+
-
terminal 3'-monophosphoryl group of substrates
-
-
-
UTP
-
inhibition in decreasing order: alpha,beta-methylene-adenosine triphosphate, ATP, UTP, GTP, CTP
vinpocetin
-
10 mU, surpresses the increase of activity, caused by the addition of 0.2 mM Ca2+
Zn2+
-
tumor cell line, N-ethylmaleimide-sensitive
5'-nucleotides
-
-
5'-nucleotides
-
end-product inhibition
ADP
-
-
AMP
-
-
AMP
-
5'-AMP, but 2'-AMP, 3'-AMP, 3': 5'cAMP and 2': 3'cAMP has no inhibiting effects
AMP
-
product inhibition of NPP1
ATP
-
-
ATP
-
inhibition in decreasing order: alpha,beta-methylene-adenosine triphosphate, ATP, UTP, GTP, CTP
dithiothreitol
-
-
dithiothreitol
-
inactivation reversed by Zn2+
EDTA
-
-
EDTA
-
inactivation reversed by Zn2+ to 90% , by Co2+ to 40% , by Ca2+ to 25%
EDTA
-
completely, inactivation reversed by Ca2+, Co2+ and, at best, with Zn2+
GTP
-
-
GTP
-
inhibition in decreasing order: alpha,beta-methylene-adenosine triphosphate, ATP, UTP, GTP, CTP
L-cysteine
-
-
L-cysteine
-
inactivation reversed by Zn2+
N-ethylmaleimide
-
-
N-ethylmaleimide
-
tumor cell line, N-ethylmaleimide-sensitive
NSC 88915
-
NSC 88915
-
a steroid inhibitor
additional information
docking simulations suggest that enzyme inhibitors bind within the catalytic pocket to prevent docking of endogenous substrates
-
additional information
-
no inhibition by L-ascorbic acid
-
additional information
-
no inhibition by adenosine, inosine, phenylalanine and caffeine
-
additional information
-
not inhibitory: 3-isobutyl-1methylxanthine, Ro 20-1724, 13-dipropyl-8-p-sulfophenylxanthine
-
additional information
-
expression of PC-1 is down-regulated during adipocyte maturation
-
additional information
-
the enzyme is not inhibited by bis(1,3,4-oxadiazol-2-methyl)-5-thione, 5-[4-pyridyl]-1,3,4-oxadiazole-2(3H)-thione, 5-[3-hydroxyphenyl]-1,3,4-oxadiazole-2(3H)-thione, 5-[4-benzyloxyphenyl]-3-octyl-1,3,4-oxadiazole-2(3H)-thione, and 5-[4-(t-butyldimethylsilyloxy)-phenyl]-1,3,4-thiadiazole-2 (3H)-thione
-
additional information
-
design and synthesis of highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5-(alpha or gamma)-thio-(alpha,beta- or beta,gamma)-methylenetriphosphate scaffold, compound configurations analsis by NMR spectroscopy, overview. Analogue 4 is not a good inhibitor. The thiophosphate groups are designed to chelate the tentative Zn2+ ions. Docking od 1-3 into the NPP1 model suggests that activity correlates with the number of H-bonds with binding site residues, overview
-
additional information
-
design, synthesis, and evaluation of new indenoisoquinolines that are dual inhibitors of both tyrosyl-DNA phosphodiesterase I and topoisomerase 1, structure-activity relationships and cytotoxicity, overview. No inhibition by methyl 2-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetate, methyl 3-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate, methyl 4-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate, methyl 5-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate, methyl 6-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoate, 3-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)amino]-3-oxopropanoic acid, methyl 3-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoate, methyl 4-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoate, methyl 5-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoate, 5-[(6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoic acid, 2-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-2-oxoacetic acid, 3-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-3-oxopropanoic acid, 4-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-4-oxobutanoic acid, 5-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-5-oxopentanoic acid, 6-[(6-(3-aminopropyl)-5,11-dioxo-6,11-dihydro-5H-indeno-[1,2-c]isoquinolin-3-yl)amino]-6-oxohexanoic acid, ethyl 2-[(6-Methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino]acetate, 2-[(6-methyl-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]-isoquinolin-3-yl)amino]acetic acid, 2-((6-(3-((tert-butoxycarbonyl)amino)propyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl)amino)acetic acid, 6-(3-bromopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline, 6-(3-azidopropyl)-5,6-dihydro-8-methoxy-3-nitro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline, 8-methoxy-6-(3-morpholinopropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione, N-[5,11-dioxo-6-[3-(2l5-triaz-1-en-2-yn-1-yl)propyl]-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide, N-[6-(3-hydroxypropyl)-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide, N-[6-(3-aminopropyl)-11-hydroxy-5-oxo-6,11-dihydro-5H-indeno[1,2-c]isoquinolin-3-yl]acetamide, 6-(3-hydroxypropyl)-3-nitro-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione, 3-cyano-5,11-dihydro-6-[3-(1H-imidazolyl)propyl]-5,11-dioxo-6,11-dihydro-5H-indeno[1,2-c]isoquinoline, 3-cyano-6,11-dihydro-5,11-dioxo-6-(3-morpholinylpropyl)-5H-indeno[1,2-c]isoquinoline, and 3-cyano-5,11-dihydro-6-[3-(dimethylamino)propyl]-5,11-dioxoindeno[1,2-c]isquinoline. Molecular modeling of the enzyme based on crystal structure PDB 1RFF
-
additional information
-
structure-based drug design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors, structure-activity relationships, molecular docking studies, and molecular modeling, overview. No inhibition by 2-(allyloxy)-3-methoxy-6-(3-morpholinopropyl)-5H-[1,3]-dioxolo[4',5':5,6]indeno [1,2-c]isoquinoline-5,12(6H)-dione, 3-methoxy-2-(3-morpholinopropoxy)-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione, 3-methoxy-2-(3-(4-methylpiperazin-1-yl)propoxy)-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]-isoquinoline-5,12(6H)-dione, methyl 2-((3-methoxy-6-(3-morpholinopropyl)-5,12-dioxo-6,12-dihydro-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]-isoquinolin-2-yl)oxy)acetate, and 2-((12-hydroxy-3-methoxy-6-(3-morpholinopropyl)-5-oxo-6,12-dihydro-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]-isoquinolin-2-yl)oxy)acetohydrazide. Antiproliferative potencies of selected O-2-modified indenoisoquinolines, overview
-
additional information
-
synthesis and evaluation of dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitors based on the indenoisoquinoline chemotype, structure-activity relationship studies, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma, Follicular
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.
Alzheimer Disease
Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking AlzheimerDisease Clinically.
Anemia
Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia.
Anemia, Sickle Cell
Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia.
Aneurysm
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
Angioid Streaks
Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6.
Ankylosis
A new Enpp1 allele, Enpp1(ttw-Ham), identified in an ICR closed colony.
Ankylosis
Ablation of Pyrophosphate Regulators Promotes Periodontal Regeneration.
Ankylosis
Analysis of meniscal degeneration and meniscal gene expression.
Ankylosis
Antagonistic interactions between osterix and pyrophosphate during cementum formation.
Ankylosis
Apoptotic bodies from endplate chondrocytes enhance the oxidative stress-induced mineralization by regulating PPi metabolism.
Ankylosis
Basic fibroblast growth factor regulates phosphate/pyrophosphate regulatory genes in stem cells isolated from human exfoliated deciduous teeth.
Ankylosis
Correction of Hypophosphatasia (Hpp) Associated Mineralization Deficiencies In vitro by Phosphate/Pyrophosphate Modulation in Periodontal Ligament Cells.
Ankylosis
Donor's age and replicative senescence favour the in-vitro mineralization potential of human fibroblasts.
Ankylosis
Genetic and pharmacologic modulation of cementogenesis via pyrophosphate regulators.
Ankylosis
Genetically Modified Mice for Studying TNAP Function.
Ankylosis
Inorganic polyphosphate induces osteoblastic differentiation.
Ankylosis
Morphological and biochemical features of obesity are associated with mineralization genes' polymorphisms.
Ankylosis
Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.
Ankylosis
The Progressive Ankylosis Protein Regulates Cementum Apposition and Extracellular Matrix Composition.
Aortic Aneurysm, Abdominal
Cyclic nucleotide phosphodiesterase 1C contributes to abdominal aortic aneurysm.
Arteriosclerosis
Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions.
Arthralgia
ENPP1 and ESR1 genotypes associated with subclassifications of craniofacial asymmetry and severity of temporomandibular disorders.
Bone Diseases
Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS).
Bone Diseases, Metabolic
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Bone Neoplasms
Determination of phosphodiesterase I activity in human blood serum.
Bone Resorption
Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25-Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor-23.
Brain Neoplasms
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Breast Neoplasms
Determination of phosphodiesterase I activity in human blood serum.
Breast Neoplasms
Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging and prognostic assessment of malignant breast cancer.
Breast Neoplasms
Enpp1: a potential facilitator of breast cancer bone metastasis.
Breast Neoplasms
High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors.
Breast Neoplasms
Identification of gene expression signature in estrogen receptor positive breast carcinoma.
Breast Neoplasms
Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1.
Breast Neoplasms
Serum phosphodiesterase I activity in breast cancer patients.
Breast Neoplasms
Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP.
Calcinosis
Bisphosphonate therapy in an infant with generalized arterial calcification with an ABCC6 mutation.
Carcinogenesis
Presence of N2-(deoxyguanosin-8-yl)-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (dG-C8-MeIQx) in human tissues.
Carcinoma
A nucleotide phosphodiesterase with preference for 2',5'-phosphodiester bonds from Ehrlich ascites carcinoma.
Carcinoma
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma.
Carcinoma
Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression.
Carcinoma
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Carcinoma
Protein and enzyme content of plasma membranes derived from Walker 256 carcinoma cells grown as ascitic or solid tumours.
Carcinoma
The significance of 5'-nucleotide phosphodiesterase isozymes in the diagnosis of liver carcinoma.
Carcinoma, Hepatocellular
Glucocorticoid hormones increase the activity of plasma membrane alkaline phosphodiesterase I in rat hepatoma cells.
Carcinoma, Hepatocellular
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Preparation of plasma membranes from line 10 and line 1 guinea pig hepatomas.
Carcinoma, Hepatocellular
The hepatic ectonucleotide pyrophosphatase/phosphodiesterase 1 gene mRNA abundance is reduced by insulin and induced by dexamethasone.
Carcinoma, Lewis Lung
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Carcinoma, Ovarian Epithelial
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Cardiovascular Diseases
ENPP1 in the Regulation of Mineralization and Beyond.
Cardiovascular Diseases
The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients.
Carotid Artery Diseases
Genetic determinants and early carotid atherosclerosis: is there a role for the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP-1) K121Q polymorphism? Preliminary results in non diabetic individuals.
Cerebrovascular Disorders
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Cholestasis, Extrahepatic
Usefulness of serum nucleotide pyrophosphatase and phosphodiesterase I activities in classifying liver disease.
Cholestasis, Intrahepatic
Pyometra in the dog--a pathophysiological investigation. V. The presence of intrahepatic cholestasis and an "acute phase reaction.".
Chondrocalcinosis
Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Regulation of PC-1 expression in osteosarcoma cells by transforming growth factor-beta.
Chondrocalcinosis
Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(? or ?)-thio-(?,?- or ?,?)-methylenetriphosphate scaffold.
Chondrocalcinosis
Investigating ANKH and ENPP1 in Slovakian families with chondrocalcinosis.
Chondrocalcinosis
Investigation of the role of ENPP1 and TNAP genes in chondrocalcinosis.
Chondrocalcinosis
Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors.
Congenital Abnormalities
Condylar geometry variation is associated with ENPP1 variant in a population of patients with dento-facial deformities.
Congenital Abnormalities
Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.
Congenital Abnormalities
INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice.
Coronary Artery Disease
ENPP1 121Q functional variant enhances susceptibility to coronary artery disease in South Indian patients with type 2 diabetes mellitus.
Coronary Artery Disease
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Coronary Artery Disease
Evaluation of NPP1 as a Novel Biomarker of Coronary Artery Disease: A Pilot Study in Human Beings.
Coronary Disease
ENPP1 K121Q (rs1044498?C?>?A) genetic polymorphism confers a high risk of susceptibility to coronary heart disease: A PRISMA-compliant article.
Cryptorchidism
Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate-dependent phosphodiesterases type 4 in abdominal testes of rats.
Cystadenoma, Serous
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Cysts
Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis.
Deafness
Hearing Loss Is Part of the Clinical Picture of ENPP1 Loss of Function Mutation.
Dementia
Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking AlzheimerDisease Clinically.
Dentofacial Deformities
ENPP1 and ESR1 genotypes influence temporomandibular disorders development and surgical treatment response in dentofacial deformities.
Diabetes Complications
The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications.
Diabetes Mellitus
An observational study of the risk of neonatal macrosomia, and early gestational diabetes associated with selected candidate genes for type 2 diabetes mellitus polymorphisms in women with gestational diabetes mellitus.
Diabetes Mellitus
Association and in silico studies of ENPP1 gene variants with type 2 diabetes mellitus in a Northern Iranian population.
Diabetes Mellitus
ENPP1 121Q functional variant enhances susceptibility to coronary artery disease in South Indian patients with type 2 diabetes mellitus.
Diabetes Mellitus
ENPP1 K121Q Genotype Not Associated with Coronary Artery Calcification in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects.
Diabetes Mellitus
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Diabetes Mellitus
Hepatic ENPP1 expression is induced in diabetic rabbits.
Diabetes Mellitus
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Diabetes Mellitus
Single locus and haplotype association of ENPP1 gene variants with the development of retinopathy among type 2 diabetic patients.
Diabetes Mellitus
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Diabetes Mellitus
The K121Q polymorphism of the plasma cell glycoprotein-1 gene is not associated with diabetes mellitus type 2 in German Caucasians.
Diabetes Mellitus
The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications.
Diabetes Mellitus
[ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients]
Diabetes Mellitus
[The analysis of association between ENPP1 K121Q polymorphism and risk factors of type 2 diabetes mellitus in ukrainian population].
Diabetes Mellitus
[The association between enpp1 rs997509 polymorphism and type 2 diabetes mellitus development in ukrainian population].
Diabetes Mellitus, Type 1
Hepatic ENPP1 expression is induced in diabetic rabbits.
Diabetes Mellitus, Type 1
Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes.
Diabetes Mellitus, Type 2
An observational study of the risk of neonatal macrosomia, and early gestational diabetes associated with selected candidate genes for type 2 diabetes mellitus polymorphisms in women with gestational diabetes mellitus.
Diabetes Mellitus, Type 2
Association and in silico studies of ENPP1 gene variants with type 2 diabetes mellitus in a Northern Iranian population.
Diabetes Mellitus, Type 2
Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPAR{gamma} and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.
Diabetes Mellitus, Type 2
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy.
Diabetes Mellitus, Type 2
Association of the ENPP1 K121Q polymorphism with susceptibility to type 2 diabetes in different populations: evidence based on 40 studies.
Diabetes Mellitus, Type 2
Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population.
Diabetes Mellitus, Type 2
Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.
Diabetes Mellitus, Type 2
Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity.
Diabetes Mellitus, Type 2
Contribution of common variants of ENPP1, IGF2BP2, KCNJ11, MLXIPL, PPAR?, SLC30A8 and TCF7L2 to the risk of type 2 diabetes in Lebanese and Tunisian Arabs.
Diabetes Mellitus, Type 2
Contribution of ENPP1, TCF7L2, and FTO polymorphisms to type 2 diabetes in mixed ancestry ethnic population of South Africa.
Diabetes Mellitus, Type 2
Diabetes and obesity-related genes and the risk of neural tube defects in the national birth defects prevention study.
Diabetes Mellitus, Type 2
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 K173Q Polymorphism Is Associated with Diabetic Nephropathy in the Taiwanese Population.
Diabetes Mellitus, Type 2
Editorial: The pleiotropic effect of the ENPP1 (PC-1) gene on insulin resistance, obesity, and type 2 diabetes.
Diabetes Mellitus, Type 2
ENPP1 121Q functional variant enhances susceptibility to coronary artery disease in South Indian patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
ENPP1 gene, insulin resistance and related clinical outcomes.
Diabetes Mellitus, Type 2
ENPP1 K121Q Genotype Not Associated with Coronary Artery Calcification in Korean Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
ENPP1 K121Q polymorphism and obesity, hyperglycaemia and type 2 diabetes in the prospective DESIR Study.
Diabetes Mellitus, Type 2
ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects.
Diabetes Mellitus, Type 2
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Diabetes Mellitus, Type 2
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians.
Diabetes Mellitus, Type 2
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes.
Diabetes Mellitus, Type 2
Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort.
Diabetes Mellitus, Type 2
Evaluation of the ENPP1 and PLIN single nucleotide polymorphisms with type 2 diabetes in a Taiwanese population: evidence for replication and gene-gene interaction.
Diabetes Mellitus, Type 2
Further Evidence For the Role of ENPP1 in Obesity: Association With Morbid Obesity in Finns.
Diabetes Mellitus, Type 2
Gender differences in the association of ENPP1 polymorphisms with type 2 diabetes in a Chinese population.
Diabetes Mellitus, Type 2
Genetic determinants of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Haplotype structure of the ENPP1 Gene and Nominal Association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study.
Diabetes Mellitus, Type 2
Hepatic ENPP1 expression is induced in diabetic rabbits.
Diabetes Mellitus, Type 2
Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(? or ?)-thio-(?,?- or ?,?)-methylenetriphosphate scaffold.
Diabetes Mellitus, Type 2
Impact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population.
Diabetes Mellitus, Type 2
Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5.
Diabetes Mellitus, Type 2
Liver ENPP1 protein increases with remission of type 2 diabetes after gastric bypass surgery.
Diabetes Mellitus, Type 2
New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals.
Diabetes Mellitus, Type 2
No evidence for association of the ENPP1 (PC-1) K121Q variant with risk of type 2 diabetes in a Japanese population.
Diabetes Mellitus, Type 2
No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians.
Diabetes Mellitus, Type 2
Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.
Diabetes Mellitus, Type 2
Single locus and haplotype association of ENPP1 gene variants with the development of retinopathy among type 2 diabetic patients.
Diabetes Mellitus, Type 2
Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans.
Diabetes Mellitus, Type 2
Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects.
Diabetes Mellitus, Type 2
Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors.
Diabetes Mellitus, Type 2
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism determines individual susceptibility to the insulin-sensitising effect of lifestyle intervention.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is associated with type 2 diabetes and related metabolic phenotypes in a Taiwanese population.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes and related metabolic traits in an Iranian population.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes in northern Chinese.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population.
Diabetes Mellitus, Type 2
The ENPP1 K121Q polymorphism modulates developing of bone disorders in type 2 diabetes: A cross sectional study.
Diabetes Mellitus, Type 2
The K121Q polymorphism in ENPP1 (PC-1) is not associated with type 2 diabetes or obesity in Korean male workers.
Diabetes Mellitus, Type 2
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Diabetes Mellitus, Type 2
Three-allele risk haplotype of ENPP1 links obesity to type 2 diabetes risk.
Diabetes Mellitus, Type 2
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
Diabetes Mellitus, Type 2
Variants of insulin-signaling inhibitor genes in type 2 diabetes and related metabolic abnormalities.
Diabetes Mellitus, Type 2
[Association and meta-analysis of ENPP1 K121Q with type 2 diabetes in Han Chinese.]
Diabetes Mellitus, Type 2
[ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients]
Diabetes Mellitus, Type 2
[ENPP1, the first example of common genetic link between childhood and adult obesity and type 2 diabetes.]
Diabetes Mellitus, Type 2
[The analysis of association between ENPP1 K121Q polymorphism and risk factors of type 2 diabetes mellitus in ukrainian population].
Diabetes Mellitus, Type 2
[The association between enpp1 rs997509 polymorphism and type 2 diabetes mellitus development in ukrainian population].
Diabetes, Gestational
An observational study of the risk of neonatal macrosomia, and early gestational diabetes associated with selected candidate genes for type 2 diabetes mellitus polymorphisms in women with gestational diabetes mellitus.
Diabetes, Gestational
Body mass index associated to rs2021966 ENPP1 polymorphism increases the risk for gestational diabetes mellitus.
Diabetic Nephropathies
Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPAR{gamma} and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.
Diabetic Nephropathies
Association between the ENPP1 K121Q polymorphism and risk of diabetic kidney disease: a systematic review and meta-analysis.
Diabetic Nephropathies
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy.
Diabetic Nephropathies
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 K173Q Polymorphism Is Associated with Diabetic Nephropathy in the Taiwanese Population.
Diabetic Nephropathies
Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes.
Diabetic Nephropathies
The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy.
Diabetic Retinopathy
Single locus and haplotype association of ENPP1 gene variants with the development of retinopathy among type 2 diabetic patients.
Dyslipidemias
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population.
Embolism
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Endometriosis
Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis.
Enthesopathy
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations.
Ependymoma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Erectile Dysfunction
[Bladder and cavernous contractility and relaxation among intracellular messengers, changes in sarcoplasmatic free calcium and phosphodiesterase activity]
Familial Hypophosphatemic Rickets
Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update.
Fatty Liver
Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population.
Fatty Liver
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Fibrous Dysplasia, Polyostotic
Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
Frontotemporal Lobar Degeneration
Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking AlzheimerDisease Clinically.
Genetic Diseases, Inborn
Bisphosphonate therapy in an infant with generalized arterial calcification with an ABCC6 mutation.
Genetic Diseases, Inborn
Cole Disease Results from Mutations in ENPP1.
Genetic Diseases, Inborn
New insights into NPP1 function: Lessons from clinical and animal studies.
Genetic Diseases, Inborn
Pseudoxanthoma Elasticum, Kidney Stones and Pyrophosphate: From a Rare Disease to Urolithiasis and Vascular Calcifications.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
Glioblastoma
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells.
Glioblastoma
Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging and prognostic assessment of malignant breast cancer.
Glioblastoma
Functional characterization of ENPP1 reveals a link between cell cycle progression and stem-like phenotype in glioblastoma.
Glioblastoma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Glioblastoma
Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.
Glioma
Agonists of the P2Y(AC)-receptor activate MAP kinase by a ras-independent pathway in rat C6 glioma.
Glioma
Cyclic AMP-dependent down regulation of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) in rat C6 glioma.
Glioma
Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists.
Glioma
gp130RB13-6-positive neural progenitor cells are susceptible to the oncogenic effect of ethylnitrosourea in pre-natal rat brain.
Glioma
NO-induced activation of cyclic GMP-dependent pathway down regulates ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) protein in rat C6 glioma.
Glucose Intolerance
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.
Glucose Intolerance
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
Hearing Loss
Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.
Hearing Loss
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Hearing Loss
Hearing Loss Is Part of the Clinical Picture of ENPP1 Loss of Function Mutation.
Hearing Loss, Conductive
Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.
Hearing Loss, Conductive
Hearing Loss Is Part of the Clinical Picture of ENPP1 Loss of Function Mutation.
Hearing Loss, Mixed Conductive-Sensorineural
Hearing Loss Is Part of the Clinical Picture of ENPP1 Loss of Function Mutation.
Heart Failure
Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
Heart Failure
ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy (GACI).
Hematologic Neoplasms
PDE4 subtypes in cancer.
Hepatitis
Nucleotide pyrophosphatase and phosphodiesterase I. Demonstration of activity in normal serum, and an increase in cholestatic liver disease.
Hepatitis C
Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.
Hepatitis, Chronic
Nucleotide pyrophosphatase and phosphodiesterase I. Demonstration of activity in normal serum, and an increase in cholestatic liver disease.
Hydrops Fetalis
Fetal hydrops, hyperechogenic arteries and pathological doppler findings at 29 weeks: prenatal presentation of generalized arterial calcification of infancy - a novel mutation in ENPP1.
Hypercementosis
Hypercementosis Associated with ENPP1 Mutations and GACI.
Hypercementosis
Reduced Orthodontic Tooth Movement in Enpp1 Mutant Mice with Hypercementosis.
Hyperglycemia
Adipose Tissue Insulin Resistance in Gestational Diabetes.
Hyperglycemia
Haplotype structure of the ENPP1 Gene and Nominal Association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study.
Hyperlipidemias
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Hyperparathyroidism, Primary
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations.
Hyperpigmentation
Hyperpigmentation in a Chinese family with autosomal dominant Cole disease.
Hypersensitivity
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Hypertension
ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy (GACI).
Hypertension
[Treatment of systemic sclerosis].
Hypertension, Pulmonary
Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
Hypertrophy, Left Ventricular
Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.
Hypertrophy, Left Ventricular
Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.
Hypertrophy, Left Ventricular
[Study on the association between gene polymorphism of ENPP1 and left ventricular hypertrophy: A Guangzhou Biobank Cohort Study-CVD.]
Hypophosphatasia
Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice.
Hypophosphatemia
Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.
Hypophosphatemia
Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.
Hypophosphatemia
Insights into dental mineralization from three heritable mineralization disorders.
Hypophosphatemia, Familial
Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.
Hypopigmentation
Hyperpigmentation in a Chinese family with autosomal dominant Cole disease.
Infections
6q16.3q23.3 duplication associated with Prader-Willi-like syndrome.
Infections
Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.
Infections
Maintenance of cyclic GMP-AMP homeostasis by ENPP1 is involved in pseudorabies virus infection.
Infections
Novel homozygous ENPP1 mutation causes generalized arterial calcifications of infancy, thrombocytopenia, and cardiovascular and central nervous system syndrome.
Infections
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Infections
The effects of increased cAMP content on inflammation, oxidative stress and PDE4 transcripts during Brucella melitensis infection.
Infections
White matter damage and chemokine induction in developing rat brain after intrauterine infection.
Infertility
Reduction in the intracellular cAMP level triggers initiation of sexual development in fission yeast.
Insulin Resistance
6q16.3q23.3 duplication associated with Prader-Willi-like syndrome.
Insulin Resistance
A Polymorphism in the Gene Encoding the Insulin Receptor Binding Protein ENPP-1 Is Associated with Decreased Glomerular Filtration Rate in an Under-Investigated Indigenous African Population.
Insulin Resistance
Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome.
Insulin Resistance
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy.
Insulin Resistance
Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population.
Insulin Resistance
Characterization of Monoclonal Antibodies to the Plasma Cell Alloantigen ENPP1.
Insulin Resistance
Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling.
Insulin Resistance
Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging and prognostic assessment of malignant breast cancer.
Insulin Resistance
Editorial: The pleiotropic effect of the ENPP1 (PC-1) gene on insulin resistance, obesity, and type 2 diabetes.
Insulin Resistance
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.
Insulin Resistance
Elevated plasma cell membrane glycoprotein levels and diminished insulin receptor autophosphorylation in obese, insulin-resistant rhesus monkeys.
Insulin Resistance
ENPP1 affects insulin action and secretion: evidences from in vitro studies.
Insulin Resistance
ENPP1 gene, insulin resistance and related clinical outcomes.
Insulin Resistance
ENPP1 K121Q polymorphism and obesity, hyperglycaemia and type 2 diabetes in the prospective DESIR Study.
Insulin Resistance
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Insulin Resistance
ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells.
Insulin Resistance
ENPP1 variants and haplotypes predispose to early onset obesity and impaired glucose and insulin metabolism in German obese children.
Insulin Resistance
Expression of membrane-bound NPP-type ecto-phosphodiesterases in rat podocytes cultured at normal and high glucose concentrations.
Insulin Resistance
Gender differences in the association of ENPP1 polymorphisms with type 2 diabetes in a Chinese population.
Insulin Resistance
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance.
Insulin Resistance
Haplotype structure of the ENPP1 Gene and Nominal Association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study.
Insulin Resistance
Hepatic ENPP1 expression is induced in diabetic rabbits.
Insulin Resistance
Impact of ENPP1 K121Q on change of insulin resistance after web-based intervention in Korean men with diabetes and impaired fasting glucose.
Insulin Resistance
Influence of Single Nucleotide Polymorphism of ENPP1 and ADIPOQ on Insulin Resistance and Obesity: A Case-Control Study in a Javanese Population.
Insulin Resistance
Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.
Insulin Resistance
Insulin signaling regulating genes: effect on T2DM and cardiovascular risk.
Insulin Resistance
Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5.
Insulin Resistance
K121Q PC-1 gene polymorphism is not associated with insulin resistance in a Spanish population.
Insulin Resistance
Liver ENPP1 protein increases with remission of type 2 diabetes after gastric bypass surgery.
Insulin Resistance
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Insulin Resistance
New Insights into the Role of ENPP1 in Insulin Resistance.
Insulin Resistance
No evidence for association of the ENPP1 (PC-1) K121Q variant with risk of type 2 diabetes in a Japanese population.
Insulin Resistance
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Insulin Resistance
Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes.
Insulin Resistance
Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.
Insulin Resistance
Role of ENPP1 on adipocyte maturation.
Insulin Resistance
Role of GALNT2 in the modulation of ENPP1 expression, and insulin signaling and action: GALNT2: A novel modulator of insulin signaling.
Insulin Resistance
Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects.
Insulin Resistance
The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals.
Insulin Resistance
The ENPP1 K121Q polymorphism determines individual susceptibility to the insulin-sensitising effect of lifestyle intervention.
Insulin Resistance
The K121Q polymorphism in ENPP1 (PC-1) is not associated with type 2 diabetes or obesity in Korean male workers.
Insulin Resistance
The K121Q polymorphism in the plasma cell membrane glycoprotein 1 gene predisposes to early myocardial infarction.
Insulin Resistance
The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy.
Insulin Resistance
The role of HSP70 on ENPP1 expression and insulin-receptor activation.
Insulin Resistance
Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.
Insulin Resistance
Uric Acid Impairs Insulin Signaling by Promoting Enpp1 Binding to Insulin Receptor in Human Umbilical Vein Endothelial Cells.
Insulin Resistance
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
Insulin Resistance
[ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients]
Insulin Resistance
[The analysis of association between ENPP1 K121Q polymorphism and risk factors of type 2 diabetes mellitus in ukrainian population].
Insulin Resistance
[The association between enpp1 rs997509 polymorphism and type 2 diabetes mellitus development in ukrainian population].
Insulinoma
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Joint Diseases
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Keratoderma, Palmoplantar
Hyperpigmentation in a Chinese family with autosomal dominant Cole disease.
Kidney Failure, Chronic
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy.
Kidney Failure, Chronic
Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure.
Kidney Failure, Chronic
Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.
Kidney Failure, Chronic
Levels of serum ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) predicts severity of abdominal aortic calcification in end-stage renal disease patients receiving regular dialysis.
Kidney Failure, Chronic
Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes.
Lewy Body Disease
Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking AlzheimerDisease Clinically.
Liver Cirrhosis
Determination of phosphodiesterase I activity in human blood serum.
Liver Cirrhosis
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Liver Cirrhosis, Biliary
Nucleotide pyrophosphatase and phosphodiesterase I. Demonstration of activity in normal serum, and an increase in cholestatic liver disease.
Liver Diseases
Nucleotide pyrophosphatase and phosphodiesterase I. Demonstration of activity in normal serum, and an increase in cholestatic liver disease.
Liver Diseases
Usefulness of serum nucleotide pyrophosphatase and phosphodiesterase I activities in classifying liver disease.
Liver Neoplasms
The significance of new abnormal isoenzymes of 5'-nucleotide phosphodiesterase in the diagnosis of human liver cancer.
Liver Neoplasms, Experimental
Intracellular distribution of 5'-ribonuclease and 5'-phosphodiesterase in the Novikoff hepatoma ascites cells.
Lung Neoplasms
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Lung Neoplasms
Determination of phosphodiesterase I activity in human blood serum.
Lung Neoplasms
Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features.
Lung Neoplasms
PDE4 subtypes in cancer.
Lung Neoplasms
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Lupus Nephritis
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Malocclusion
ENPP1 and ESR1 genotypes associated with subclassifications of craniofacial asymmetry and severity of temporomandibular disorders.
Medulloblastoma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Meningioma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Metabolic Syndrome
Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome.
Metabolic Syndrome
Association of genetic variation in ENPP1 with obesity-related phenotypes.
Metabolic Syndrome
Association of K121Q Polymorphism in Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 with Clinical Characteristics of Metabolic Syndrom.
Metabolic Syndrome
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy.
Metabolic Syndrome
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.
Metabolic Syndrome
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Metabolic Syndrome
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Metabolic Syndrome
[The association between enpp1 rs997509 polymorphism and type 2 diabetes mellitus development in ukrainian population].
Mouth Neoplasms
Metabolic Regulation of Glycolysis and AMP Activated Protein Kinase Pathways during Black Raspberry-Mediated Oral Cancer Chemoprevention.
Mouth Neoplasms
MicroRNA-133 Targets Phosphodiesterase 1C in Drosophila and Human Oral Cancer Cells to Regulate Epithelial-Mesenchymal Transition.
Myalgia
ENPP1 and ESR1 genotypes associated with subclassifications of craniofacial asymmetry and severity of temporomandibular disorders.
Myocardial Infarction
Association of Genetic Variants of MTHFR, ENPP1, and ADIPOQ with Myocardial Infarction in Egyptian Patients.
Myocardial Infarction
Determination of phosphodiesterase I activity in human blood serum.
Myocardial Infarction
ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.
Myocardial Infarction
The K121Q polymorphism in the plasma cell membrane glycoprotein 1 gene predisposes to early myocardial infarction.
Myocardial Ischemia
[ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients]
Myringosclerosis
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Neoplasm Metastasis
Enpp1: a potential facilitator of breast cancer bone metastasis.
Neoplasm Metastasis
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Neoplasm Metastasis
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasms
5'-Nucleotide phosphodiesterase and alkaline phosphatase in tumor cells: evidence for existence of novel species in the cytosol.
Neoplasms
A novel tumor-associated molecular species of 5'-nucleotide phosphodiesterase.
Neoplasms
A nucleotide phosphodiesterase with preference for 2',5'-phosphodiester bonds from Ehrlich ascites carcinoma.
Neoplasms
Affinity purification and cDNA cloning of rat neural differentiation and tumor cell surface antigen gp130RB13-6 reveals relationship to human and murine PC-1.
Neoplasms
Association of K121Q polymorphism in ENPP1 (PC-1) with BMI in Caucasian and African-American adults.
Neoplasms
Autotaxin, tumor motility-stimulating exophosphodiesterase.
Neoplasms
Characterization of a new plasma membrane-associated ecto-5'-phosphodiesterase/nucleotide-pyrophosphatase from rat hepatocarcinoma AS-30D cells.
Neoplasms
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Neoplasms
Crystal structures of human ENPP1 in apo and bound forms.
Neoplasms
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.
Neoplasms
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
Neoplasms
Development of a High-Throughput Assay to Identify Inhibitors of ENPP1.
Neoplasms
Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging and prognostic assessment of malignant breast cancer.
Neoplasms
Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features.
Neoplasms
Effect of Pterostilbene, a Natural Derivative of Resveratrol, in the Treatment of Colorectal Cancer through Top1/Tdp1-Mediated DNA Repair Pathway.
Neoplasms
ENPP1 in the Regulation of Mineralization and Beyond.
Neoplasms
ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1.
Neoplasms
Enpp1: a potential facilitator of breast cancer bone metastasis.
Neoplasms
Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression.
Neoplasms
Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity.
Neoplasms
Glycolipids and myelin proteins in human oligodendrogliomas.
Neoplasms
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Neoplasms
Identification of a phosphodiesterase I/nucleotide pyrophosphatase-related gene mRNA in rat vascular smooth muscle cells by the differential display approach.
Neoplasms
Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.
Neoplasms
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer.
Neoplasms
Incorporation of cis-dichlorobiscyclopentylamineplatinum (II) into liposomes enhances its uptake by ADJ/PC6A tumour cells: comparative effects of the free and liposome-incorporated drug on the cyclic 3'-5' nucleotide phosphodiesterase activity.
Neoplasms
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Neoplasms
Mining of RNA Methylation-Related Genes and Elucidation of Their Molecular Biology in Gallbladder Carcinoma.
Neoplasms
New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors.
Neoplasms
Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topote?an on in vivo tumor models.
Neoplasms
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Neoplasms
PDE4 subtypes in cancer.
Neoplasms
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasms
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Neoplasms
Plasma membrane associated enzymes of mammary tumours as the biochemical indicators of metastasizing capacity. Analyses of enriched plasma membrane preparations.
Neoplasms
Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells.
Neoplasms
Preparation of plasma membranes from line 10 and line 1 guinea pig hepatomas.
Neoplasms
Protein and enzyme content of plasma membranes derived from Walker 256 carcinoma cells grown as ascitic or solid tumours.
Neoplasms
Re-awakening Innate Immune Signaling in Cancer: The Development of Highly Potent ENPP1 Inhibitors.
Neoplasms
Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I.
Neoplasms
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Neoplasms
Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
Neoplasms
Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP.
Neoplasms
Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors.
Neoplasms
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Neoplasms
The expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP1) is correlated with astrocytic tumor grade.
Neoplasms
The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo.
Nephrocalcinosis
Genetic modulation of nephrocalcinosis in mouse models of ectopic mineralization: the Abcc6(tm1Jfk) and Enpp1(asj) mutant mice.
Neuroblastoma
Induction of cyclic AMP and cyclic GMP 3':5'-cyclic nucleotide phosphodiesterase activities in neuroblastoma lines under differentiating conditions.
Neurodegenerative Diseases
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.
Nevus
Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
Non-alcoholic Fatty Liver Disease
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Obesity
6q16.3q23.3 duplication associated with Prader-Willi-like syndrome.
Obesity
An integrative systems genetics approach reveals potential causal genes and pathways related to obesity.
Obesity
Analysis of the contribution of FTO, NPC1, ENPP1, NEGR1, GNPDA2 and MC4R genes to obesity in Mexican children.
Obesity
Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome.
Obesity
Association of genetic variation in ENPP1 with obesity-related phenotypes.
Obesity
Association of K121Q polymorphism in ENPP1 (PC-1) with BMI in Caucasian and African-American adults.
Obesity
Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population.
Obesity
Association of the ENPP1 rs997509 polymorphism with obesity in South African mixed ancestry learners.
Obesity
Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity.
Obesity
Diabetes and obesity-related genes and the risk of neural tube defects in the national birth defects prevention study.
Obesity
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 K173Q Polymorphism Is Associated with Diabetic Nephropathy in the Taiwanese Population.
Obesity
Editorial: The pleiotropic effect of the ENPP1 (PC-1) gene on insulin resistance, obesity, and type 2 diabetes.
Obesity
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.
Obesity
ENPP1 K121Q polymorphism and obesity, hyperglycaemia and type 2 diabetes in the prospective DESIR Study.
Obesity
ENPP1 variants and haplotypes predispose to early onset obesity and impaired glucose and insulin metabolism in German obese children.
Obesity
ENPP1/PC-1 gene K121Q polymorphism is associated with obesity in European adult populations: evidence from a meta-analysis involving 24,324 subjects.
Obesity
Further Evidence For the Role of ENPP1 in Obesity: Association With Morbid Obesity in Finns.
Obesity
Hepatic ENPP1 expression is induced in diabetic rabbits.
Obesity
Influence of Single Nucleotide Polymorphism of ENPP1 and ADIPOQ on Insulin Resistance and Obesity: A Case-Control Study in a Javanese Population.
Obesity
MC4R and ENPP1 gene polymorphisms and their implication in maternal and neonatal risk for obesity.
Obesity
Morphological and biochemical features of obesity are associated with mineralization genes' polymorphisms.
Obesity
New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals.
Obesity
No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians.
Obesity
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Obesity
Possible role for ENPP1 polymorphism in obesity but not for INSIG2 and PLIN variants.
Obesity
Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects.
Obesity
The ENPP1 K121Q polymorphism is associated with type 2 diabetes and related metabolic phenotypes in a Taiwanese population.
Obesity
The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population.
Obesity
The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients.
Obesity
The K121Q polymorphism in ENPP1 (PC-1) is not associated with type 2 diabetes or obesity in Korean male workers.
Obesity
The Q121 variant of ENPP1 may protect from childhood overweight/obesity in the Italian population.
Obesity
Three-allele risk haplotype of ENPP1 links obesity to type 2 diabetes risk.
Obesity
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
Obesity
[ENPP1, the first example of common genetic link between childhood and adult obesity and type 2 diabetes.]
Obesity
[The association between enpp1 rs997509 polymorphism and type 2 diabetes mellitus development in ukrainian population].
Obesity, Morbid
Further Evidence For the Role of ENPP1 in Obesity: Association With Morbid Obesity in Finns.
Oligodendroglioma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Ossification of Posterior Longitudinal Ligament
A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene.
Osteoarthritis
Association of ENPP1 gene polymorphisms with hand osteoarthritis in a Chuvasha population.
Osteoarthritis
Crystals in hand.
Osteoarthritis
ENPP1 in the Regulation of Mineralization and Beyond.
Osteoarthritis
Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(? or ?)-thio-(?,?- or ?,?)-methylenetriphosphate scaffold.
Osteoarthritis
Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors.
Osteomalacia
Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization.
Osteoporosis
Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions.
Osteoporosis
Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization.
Osteoporosis
High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.
Osteoporosis
Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.
Osteosarcoma
Expression of the nucleoside triphosphate pyrophosphohydrolase PC-1 is induced by basic fibroblast growth factor (bFGF) and modulated by activation of the protein kinase A and C pathways in osteoblast-like osteosarcoma cells.
Otitis
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Otitis Media
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Otitis Media with Effusion
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Ovarian Cysts
Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis.
Ovarian Neoplasms
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Overweight
MC4R and ENPP1 gene polymorphisms and their implication in maternal and neonatal risk for obesity.
Overweight
The Q121 variant of ENPP1 may protect from childhood overweight/obesity in the Italian population.
Pediatric Obesity
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.
Pediatric Obesity
The Q121 variant of ENPP1 may protect from childhood overweight/obesity in the Italian population.
Pediatric Obesity
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
Pediatric Obesity
[ENPP1, the first example of common genetic link between childhood and adult obesity and type 2 diabetes.]
Peripheral Arterial Disease
The K121Q polymorphism of ENPP1 and peripheral arterial disease.
Peripheral Nervous System Diseases
TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo.
Peritonitis
Generalized Arterial Calcification of Infancy Associated with Meconium Peritonitis: A Case Report and Review of the Literature.
phosphodiesterase i deficiency
Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies.
phosphodiesterase i deficiency
Enpp1 inhibits ectopic joint calcification and maintains articular chondrocytes by repressing hedgehog signaling.
phosphodiesterase i deficiency
ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP.
phosphodiesterase i deficiency
Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization.
phosphodiesterase i deficiency
Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.
phosphodiesterase i deficiency
INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice.
phosphodiesterase i deficiency
Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression.
phosphodiesterase i deficiency
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI).
phosphodiesterase i deficiency
Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice.
phosphodiesterase i deficiency
Vascular calcification is dependent on plasma levels of pyrophosphate.
Plasmacytoma
Identification of nucleotide pyrophosphatase/alkaline phosphodiesterase I activity associated with the mouse plasma cell differentiation antigen PC-1.
Plasmacytoma
Modulation of nucleotide pyrophosphatase in plasmacytoma cells.
Polycystic Ovary Syndrome
Association of the polymorphism of codon 121 in the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene with polycystic ovary syndrome in Chinese women.
Polycystic Ovary Syndrome
Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population.
Polycystic Ovary Syndrome
The 121Q allele of the plasma cell membrane glycoprotein 1 gene predisposes to polycystic ovary syndrome.
Pseudorabies
Maintenance of cyclic GMP-AMP homeostasis by ENPP1 is involved in pseudorabies virus infection.
Pseudoxanthoma Elasticum
Cellular signaling in pseudoxanthoma elasticum: an update.
Pseudoxanthoma Elasticum
Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene.
Pseudoxanthoma Elasticum
Effects of Different Variants in the ENPP1 Gene on the Functional Properties of Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1.
Pseudoxanthoma Elasticum
Efficiency of exome sequencing for the molecular diagnosis of pseudoxanthoma elasticum.
Pseudoxanthoma Elasticum
Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6.
Pseudoxanthoma Elasticum
Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin.
Pseudoxanthoma Elasticum
Genetic Heterogeneity of Pseudoxanthoma Elasticum: The Chinese Signature Profile of ABCC6 and ENPP1 Mutations.
Pseudoxanthoma Elasticum
Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel.
Pseudoxanthoma Elasticum
Homology Modeling and Virtual Screening of Proteins Related to PXE and PXE-like Diseases: Insights for Overlapping Metabolites.
Pseudoxanthoma Elasticum
Oral administration of pyrophosphate inhibits connective tissue calcification.
Pseudoxanthoma Elasticum
Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate.
Pseudoxanthoma Elasticum
Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE).
Pulmonary Arterial Hypertension
[Treatment of systemic sclerosis].
Renal Insufficiency
Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.
Renal Insufficiency, Chronic
The bone-vascular axis in chronic kidney disease.
Rhabdomyosarcoma
Tyrosyl-DNA phosphodiesterase 1 (TDP1) and Poly (ADP-Ribose) Polymerase-1 (PARP1) deficiency are cytotoxic to rhabdomyosarcoma cells.
Rickets
Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies.
Rickets
Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update.
Rickets
Mutation of SGK3, a novel regulator of renal phosphate transport, causes autosomal dominant hypophosphatemic rickets.
Rickets
Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets.
Rickets
Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification.
Rickets
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI).
Rickets, Hypophosphatemic
A Novel PHEX Mutation in Japanese Patients with X-Linked Hypophosphatemic Rickets.
Rickets, Hypophosphatemic
A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene.
Rickets, Hypophosphatemic
Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.
Rickets, Hypophosphatemic
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations.
Rickets, Hypophosphatemic
Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.
Rickets, Hypophosphatemic
Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies.
Rickets, Hypophosphatemic
Ectopic Mineralization and Conductive Hearing Loss in Enpp1asj Mutant Mice, a New Model for Otitis Media and Tympanosclerosis.
Rickets, Hypophosphatemic
Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency.
Rickets, Hypophosphatemic
INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice.
Rickets, Hypophosphatemic
Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets.
Rickets, Hypophosphatemic
PHEX 3'-UTR c.*231A?>?G Near The Polyadenylation Signal Is A Relatively Common, Mild, American Mutation That Masquerades As Sporadic Or X-Linked Recessive Hypophosphatemia.
Rickets, Hypophosphatemic
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI).
Rickets, Hypophosphatemic
[Homozygous ectonucleotide pyrophosphatase/phosphodiesterase 1 variants in a girl with hypophosphatemic rickets and literature review].
Schistosomiasis
Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis.
Seizures
Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration.
Spinocerebellar Ataxias
Identification of novel inhibitors for the tyrosyl-DNA-phosphodiesterase 1 (Tdp1) mutant SCAN1 using virtual screening.
Spinocerebellar Ataxias
SCAN1-TDP1 trapping on mitochondrial DNA promotes mitochondrial dysfunction and mitophagy.
Spinocerebellar Ataxias
Spinocerebellar ataxia with axonal neuropathy type 1 revisited.
Spinocerebellar Ataxias
TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo.
Spinocerebellar Degenerations
ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells.
Stroke
Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia.
Stroke
Biomarkers and genetic modulators of cerebral vasculopathy in sub-Saharan ancestry children with sickle cell anemia.
Stroke
Genetic mapping and exome sequencing identify two mutations associated with stroke protection in pediatric patients with sickle cell anemia.
Stroke
Utilizing Whole-Exome Sequencing to Characterize the Phenotypic Variability of Sickle Cell Disease.
Temporomandibular Joint Disorders
ENPP1 and ESR1 genotypes associated with subclassifications of craniofacial asymmetry and severity of temporomandibular disorders.
Temporomandibular Joint Disorders
ENPP1 and ESR1 genotypes influence temporomandibular disorders development and surgical treatment response in dentofacial deformities.
Teratocarcinoma
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Thrombocytopenia
Novel homozygous ENPP1 mutation causes generalized arterial calcifications of infancy, thrombocytopenia, and cardiovascular and central nervous system syndrome.
Thrombosis
PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Tourette Syndrome
Association of tyrosyl-DNA phosphodiesterase 1 polymorphism with Tourette syndrome in Taiwanese patients.
Triple Negative Breast Neoplasms
Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging and prognostic assessment of malignant breast cancer.
Tuberculosis
Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase.
Uremia
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Vascular Calcification
Alkalosis and Dialytic Clearance of Phosphate Increases Phosphatase Activity: A Hidden Consequence of Hemodialysis.
Vascular Calcification
Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS).
Vascular Calcification
ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy (GACI).
Vascular Calcification
Impact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population.
Vascular Calcification
Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure.
Vascular Calcification
Insights into dental mineralization from three heritable mineralization disorders.
Vascular Calcification
Levels of serum ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) predicts severity of abdominal aortic calcification in end-stage renal disease patients receiving regular dialysis.
Vascular Calcification
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Vascular Calcification
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI).
Vascular Calcification
Pseudoxanthoma elasticum with prominent arterial calcifications evoking CD73 deficiency.
Vascular Calcification
Vascular calcification is dependent on plasma levels of pyrophosphate.
Viremia
Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.
Virus Diseases
Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.
Virus Diseases
Maintenance of cyclic GMP-AMP homeostasis by ENPP1 is involved in pseudorabies virus infection.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.015
(2R,4R,4aR,7R,8aS)-4,7-dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol
Homo sapiens
at pH 8.0 and 26°C
0.015
(2R,4S,4aR,7R,8aS)-4,7-dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol
Homo sapiens
at pH 8.0 and 26°C
0.004
2,2,2-trifluoro-N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.0014
2,2,2-trifluoro-N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.00123
3-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
Homo sapiens
pH and temperature not specified in the publication
0.0012
3-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
Homo sapiens
pH and temperature not specified in the publication
0.01
3-((3,4,5-trimethoxybenzyl)oxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
Homo sapiens
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00493
3-((3-methoxybenzyl)oxy)-7,8,9,10-tetrahydro-6Hbenzo[c]chromen-6-one
Homo sapiens
pH and temperature not specified in the publication
0.00145
3-(2-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
Homo sapiens
pH and temperature not specified in the publication
0.00562
3-(benzyloxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
Homo sapiens
pH and temperature not specified in the publication
0.01
4-methyl-7-((3,4,5-trimethoxybenzyl)oxy)-2H-chromen-2-one
Homo sapiens
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.001
6,6'-[(1R,2R,3S,4S)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-diyl]di(2H-pyran-2-one)
Homo sapiens
at pH 8.0 and 26°C
0.00137
7-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
pH and temperature not specified in the publication
0.00156
7-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-4-methyl-2H-chromen-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000675
7-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
pH and temperature not specified in the publication
0.00431
7-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-4-methyl-2H-chromen-2-one
Homo sapiens
pH and temperature not specified in the publication
0.01
7-((3,4,5-trimethoxybenzyl)oxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
7-((3-methoxybenzyl) oxy)-4-methyl-2H-chromen-2-one
Homo sapiens
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
7-((3-methoxybenzyl)oxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00109
7-(2-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
pH and temperature not specified in the publication
0.00917
7-(benzyloxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one
Homo sapiens
pH and temperature not specified in the publication
0.00528
7-(benzyloxy)-4-methyl-2H-chromen-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0000675
7-[[(1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methoxy]-2,3-dihydrobenzo[b]cyclopenta[d]pyran-4(1H)-one
Homo sapiens
at pH 8.0 and 26°C
0.0012
furamidine
Homo sapiens
at pH 8.0 and 26°C
0.0004
methyl-3,4-dephostatin
Homo sapiens
pH and temperature not specified in the publication
0.0035
N-(3,7-dimethyloct-6-en-1-yl)tricyclo[3.3.1.1(3,7)]decan-2-amine
Homo sapiens
at pH 8.0 and 26°C
0.0029
N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.0033
N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)benzamide
Homo sapiens
at pH 8.0 and 26°C
0.0028
N-(5-((2R,4R,4aR,7R,8aS)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-1-carboxamide
Homo sapiens
at pH 8.0 and 26°C
0.0058
N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.005
N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2yl)benzamide
Homo sapiens
at pH 8.0 and 26°C
0.00124
N-(5-((2R,4S,4aR,7R,8aS)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-1-carboxamide
Homo sapiens
at pH 8.0 and 26°C
0.009
NSC88915
Homo sapiens
pH and temperature not specified in the publication
0.0006
(RP)-adenosine 5'-(alpha-thio-beta,gamma-dichloromethylene)triphosphate
Homo sapiens
-
pH 8.5, 37°C, enzyme NPP1
0.0163
(RP)-adenosine 5'-(alpha-thio-beta,gamma-methylene)triphosphate
Homo sapiens
-
pH 8.5, 37°C, enzyme NPP1
0.0312
(SP)-adenosine 5'-(alpha-thio-beta,gamma-dichloromethylene)triphosphate
Homo sapiens
-
pH 8.5, 37°C, enzyme NPP1
0.0187
(SP)-adenosine 5'-(alpha-thio-beta,gamma-methylene)triphosphate
Homo sapiens
-
pH 8.5, 37°C, enzyme NPP1
0.01
2,2,2-trifluoro-N-(8-(trifluoromethyl)benzo[f][1,2,3,4,5]pentathiepin-6-yl)acetamide
Homo sapiens
IC50 above 0.1 mM, at pH 8.0 and 26°C
0.00022
2-(dibutylamino)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.00128
2-(piperidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.0037
2-(pyrrolidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.00162
2-morpholino-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide
Homo sapiens
at pH 8.0 and 26°C
0.00366
3-(piperidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
Homo sapiens
at pH 8.0 and 26°C
0.00603
3-(pyrrolidin-1-yl)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
Homo sapiens
at pH 8.0 and 26°C
0.0013
3-morpholino-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)propanamide
Homo sapiens
at pH 8.0 and 26°C
0.494
5-[3-benzyloxyphenyl]-1,3,4-oxadiazole-2(3H)-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.368
5-[4-(t-butyldimethylsilyloxy)-phenyl]-1,3,4-oxadiazole-2(3H)-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.628
5-[4-benzyloxyphenyl]-1,3,4-oxadiazole-2(3H)-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.9
5-[4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.998
5-[4-pyridyl]-1,3,4-thiadiazole-2(3H)-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.00152
6,6'-[propane-1,3-diylbis(iminopropane-3,1-diyl)]bis(5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione)
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.014
6-(10-aminodecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0128
6-(11-aminoundecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0151
6-(12-aminododecyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0553
6-(2-aminoethyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0295
6-(3-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0223
6-(4-aminobutyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0175
6-(5-aminopentyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.025
6-(6-aminohexyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.0288
6-(7-aminoheptyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.048
6-(8-aminooctyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.047
6-(9-aminononyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione
Homo sapiens
-
pH 7.5, 25°C, recombinant enzyme
0.00039
adenosine 5'-(gamma-thio-beta,gamma-methylene)triphosphate
Homo sapiens
-
pH 8.5, 37°C, enzyme NPP1
0.01
aminobenzopentathiepine
Homo sapiens
IC50 above 0.01 mM, at pH 8.0 and 26°C
0.467
bis(1,3,4-oxadiazol-2-propyl)-5-thione
Homo sapiens
-
in 20 mM Tris-HCl, pH 8.0, 0.5 M NaCl and 1 mM CaCl2, at 37°C
0.00245
N-(2-[1-[2-(2-methyl-1H-imidazol-1-yl)pyrimidin-4-yl]piperidin-4-yl]ethyl)sulfuric diamide
Homo sapiens
-
-
0.0006
N-(2-[1-[6-(2-methyl-1H-imidazol-1-yl)pyrimidin-4-yl]piperidin-4-yl]ethyl)sulfuric diamide
Homo sapiens
-
-
0.01
N-phenyl-2-(piperidin-1-yl)acetamide
Homo sapiens
IC50 above 0.1 mM, at pH 8.0 and 26°C
0.01
N-phenyl-2-(pyrrolidin-1-yl)acetamide
Homo sapiens
IC50 above 0.1 mM, at pH 8.0 and 26°C
0.000035
N-[2-(1-[6,7-dimethoxy-2-[(E)-2-(pyridin-3-yl)ethenyl]quinazolin-4-yl]piperidin-4-yl)ethyl]sulfuric diamide
Homo sapiens
-
-
0.000214
N-[2-[1-(2-ethyl-6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
Homo sapiens
-
-
0.000036
N-[2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
Homo sapiens
-
-
0.00598
N-[2-[1-(6-chloroquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
Homo sapiens
-
-
0.01
N-[2-[1-(7-chloroquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
Homo sapiens
-
above
0.000187
N-[2-[1-(7-methoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
Homo sapiens
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Sakura, H.; Nagashima, S.; Nakashima, A.; Maeda, M.
Characterization of fetal serum 5'-nucleotide phosphodiesterase: A novel function as a platelet aggregation inhibitor in fetal circulation
Thromb. Res.
91
83-89
1998
Homo sapiens
brenda
Fukazawa, H.; Nishimura, T.; Tanaka, N.; Suzuki, H.
5'-Nucleotide phosphodiesterase and alkaline phosphatase in tumor cells: evidence for existence of novel species in the cytosol
Biochim. Biophys. Acta
966
99-106
1988
Bos taurus, Homo sapiens, Mus musculus
brenda
Ito, K.; Yamamoto, T.; Minamiura, N.
Phosphodiesterase I in human urine: purification and characterization of the enzyme
J. Biochem.
102
359-367
1987
Homo sapiens
brenda
Razzell, W.E.
Tissue and intracellular distribution of two phophodiesterases
J. Biol. Chem.
236
3028-3030
1961
Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Maruyama, E.; Takashima, S.
Characterization of over-expressed alkaline phosphodiesterase I in tumor-derived fibroblasts from patients with neurofibromatosis
Cell Biochem. Funct.
11
271-277
1993
Homo sapiens
brenda
Belli, S.I.; Goding, J.W.
Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities
Eur. J. Biochem.
226
433-443
1994
Homo sapiens, Mus musculus
brenda
Luthje, J.; Ogilvie, A.
Catabolism of Ap3A and Ap4A in human plasma. Purification and characterization of a glycoprotein complex with 5'-nucleotide phosphodiesterase activity
Eur. J. Biochem.
149
119-127
1985
Homo sapiens
brenda
Picher, M.; Boucher, R.C.
Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways
Am. J. Respir. Cell Mol. Biol.
23
255-261
2000
Homo sapiens
brenda
Acosta Maldonado, P.; de Carvalho Correa, M.; Vargas Becker, L.; Flores, C.; Beatriz Moretto, M.; Morsch, V.; Chitolina Schetinger, M.R.
Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine Ddaminase (ADA) activities in patients with uterine cervix neoplasia
Clin. Biochem.
46
400-406
2008
Homo sapiens
brenda
Keene, K.L.; Mychaleckyj, J.C.; Smith, S.G.; Leak, T.S.; Perlegas, P.S.; Langefeld, C.D.; Freedman, B.I.; Rich, S.S.; Bowden, D.W.; Sale, M.M.
Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy
Diabetes
57
1057-1062
2008
Homo sapiens
brenda
Goldfine, I.D.; Maddux, B.A.; Youngren, J.F.; Reaven, G.; Accili, D.; Trischitta, V.; Vigneri, R.; Frittitta, L.
The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities
Endocr. Rev.
29
62-75
2008
Homo sapiens
brenda
Santoro, N.; Cirillo, G.; Lepore, M.G.; Palma, A.; Amato, A.; Savarese, P.; Marzuillo, P.; Grandone, A.; Perrone, L.; Del Giudice, E.M.
Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity
J. Clin. Endocrinol. Metab.
94
300-305
2009
Homo sapiens
brenda
Takahama, Y.; Uto, H.; Kanmura, S.; Oketani, M.; Ido, A.; Kusumoto, K.; Hasuike, S.; Nagata, K.; Hayashi, K.; Stuver, S.; Okayama, A.; Tsubouchi, H.
Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan
J. Gastroenterol.
43
942-950
2008
Homo sapiens
brenda
Patel, S.D.; Habeski, W.M.; Cheng, A.C.; de la Cruz, E.; Loh, C.; Kablaoui, N.M.
Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design
Bioorg. Med. Chem. Lett.
19
3339-3343
2009
Homo sapiens
brenda
Li, Y.; Liu, J.; Hudson, M.; Kim, S.; Hatch, N.E.
FGF2 promotes Msx2 stimulated PC-1 expression via Frs2/MAPK signaling
J. Cell. Biochem.
111
1346-1358
2010
Homo sapiens
brenda
Shimizu, K.; Murata, T.; Watanabe, Y.; Sato, C.; Morita, H.; Tagawa, T.
Characterization of phosphodiesterase 1 in human malignant melanoma cell lines
Anticancer Res.
29
1119-1122
2009
Homo sapiens
brenda
Khan, K.M.; Fatima, N.; Rasheed, M.; Jalil, S.; Ambreen, N.; Perveen, S.; Choudhary, M.I.
1,3,4-Oxadiazole-2(3H)-thione and its analogues: a new class of non-competitive nucleotide pyrophosphatases/phosphodiesterases 1 inhibitors
Bioorg. Med. Chem.
17
7816-7822
2009
Bothrops atrox, Homo sapiens
brenda
Interthal, H.; Champoux, J.J.
Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1
Biochem. J.
436
559-566
2011
Homo sapiens
brenda
Perego, P.; Cossa, G.; Tinelli, S.; Corna, E.; Carenini, N.; Gatti, L.; De Cesare, M.; Ciusani, E.; Zunino, F.; Luison, E.; Canevari, S.; Zaffaroni, N.; Beretta, G.L.
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition
Biochem. Pharmacol.
83
27-36
2011
Homo sapiens
brenda
Lebedeva, N.A.; Rechkunova, N.I.; Lavrik, O.I.
AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1
FEBS Lett.
585
683-686
2011
Homo sapiens
brenda
Fehr, M.; Baechler, S.; Kropat, C.; Mielke, C.; Boege, F.; Pahlke, G.; Marko, D.
Repair of DNA damage induced by the mycotoxin alternariol involves tyrosyl-DNA phosphodiesterase 1
Mycotoxin Res.
26
247-256
2010
Homo sapiens
brenda
Lee, S.Y.; Kim, H.; Hwang, H.J.; Jeong, Y.M.; Na, S.H.; Woo, J.C.; Kim, S.G.
Identification of tyrosyl-DNA phosphodiesterase as a novel DNA damage repair enzyme in Arabidopsis
Plant Physiol.
154
1460-1469
2010
Homo sapiens, Arabidopsis thaliana (Q8H1D9)
brenda
Conda-Sheridan, M.; Reddy, P.V.; Morrell, A.; Cobb, B.T.; Marchand, C.; Agama, K.; Chergui, A.; Renaud, A.; Stephen, A.G.; Bindu, L.K.; Pommier, Y.; Cushman, M.
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1)
J. Med. Chem.
56
182-200
2013
Homo sapiens
brenda
Lebedeva, N.A.; Rechkunova, N.I.; El-Khamisy, S.F.; Lavrik, O.I.
Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic sites
Biochimie
94
1749-1753
2012
Homo sapiens
brenda
Lebedeva, N.A.; Rechkunova, N.I.; Ishchenko, A.A.; Saparbaev, M.; Lavrik, O.I.
The mechanism of human tyrosyl-DNA phosphodiesterase 1 in the cleavage of AP site and its synthetic analogs
DNA Repair
12
1037-1042
2013
Homo sapiens
brenda
Comeaux, E.Q.; van Waardenburg, R.C.
Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target
Drug Metab. Rev.
46
494-507
2014
Canis lupus familiaris (E2REL5), Gallus gallus (F1NSQ5), Saccharomyces cerevisiae (P38319), Rattus norvegicus (Q4G056), Mus musculus (Q8BJ37), Homo sapiens (Q9NUW8), Drosophila melanogaster (Q9VQM4), Saccharomyces cerevisiae ATCC 204508 (P38319)
brenda
Murai, J.; Huang, S.Y.; Das, B.B.; Dexheimer, T.S.; Takeda, S.; Pommier, Y.
Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells
J. Biol. Chem.
287
12848-12857
2012
Gallus gallus, Homo sapiens
brenda
Traini, M.; Quinn, C.M.; Sandoval, C.; Johansson, E.; Schroder, K.; Kockx, M.; Meikle, P.J.; Jessup, W.; Kritharides, L.
Sphingomyelin phosphodiesterase-like 3A (SMPDL3A) is a novel nucleotide phosphodiesterase regulated by cholesterol in human macrophages
J. Biol. Chem.
289
32895-32913
2014
Mus musculus (P70158), Homo sapiens (Q92484), Homo sapiens, Mus musculus C57 black (P70158)
brenda
Nguyen, T.X.; Morrell, A.; Conda-Sheridan, M.; Marchand, C.; Agama, K.; Bermingham, A.; Bermingam, A.; Stephen, A.G.; Chergui, A.; Naumova, A.; Fisher, R.; OKeefe, B.R.; Pommier, Y.; Cushman, M.
Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors
J. Med. Chem.
55
4457-4478
2012
Homo sapiens
brenda
Lv, P.C.; Agama, K.; Marchand, C.; Pommier, Y.; Cushman, M.
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors
J. Med. Chem.
57
4324-4336
2014
Homo sapiens
brenda
Nadel, Y.; Lecka, J.; Gilad, Y.; Ben-David, G.; Foerster, D.; Reiser, G.; Kenigsberg, S.; Camden, J.; Weisman, G.A.; Senderowitz, H.; Sevigny, J.; Fischer, B.
Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5-(alpha or gamma)-thio-(alpha,beta- or beta,gamma)-methylenetriphosphate scaffold
J. Med. Chem.
57
4677-4691
2014
Homo sapiens
brenda
Zakharenko, A.; Khomenko, T.; Zhukova, S.; Koval, O.; Zakharova, O.; Anarbaev, R.; Lebedeva, N.; Korchagina, D.; Komarova, N.; Vasiliev, V.; Reynisson, J.; Volcho, K.; Salakhutdinov, N.; Lavrik, O.
Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety
Bioorg. Med. Chem.
23
2044-2052
2015
Homo sapiens (Q9NKW8)
brenda
Khomenko, T.; Zakharenko, A.; Odarchenko, T.; Arabshahi, H.J.; Sannikova, V.; Zakharova, O.; Korchagina, D.; Reynisson, J.; Volcho, K.; Salakhutdinov, N.; Lavrik, O.
New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties
Bioorg. Med. Chem.
24
5573-5581
2016
Homo sapiens (Q9NUW8)
brenda
Bautista Nino, P.K.; Durik, M.; Danser, A.H.; de Vries, R.; Musterd-Bhaggoe, U.M.; Meima, M.E.; Kavousi, M.; Ghanbari, M.; Hoeijmakers, J.H.; O'Donnell, C.J.; Franceschini, N.; Janssen, G.M.; De Mey, J.G.; Liu, Y.; Shanahan, C.M.; Franco, O.H.; Dehghan, A.; Roks, A.J.
Phosphodiesterase 1 regulation is a key mechanism in vascular aging
Clin. Sci.
129
1061-1075
2015
Homo sapiens
brenda
Li-Zhulanov, N.S.; Zakharenko, A.L.; Chepanova, A.A.; Patel, J.; Zafar, A.; Volcho, K.P.; Salakhutdinov, N.F.; Reynisson, J.; Leung, I.K.H.; Lavrik, O.I.
A novel class of tyrosyl-DNA phosphodiesterase 1 inhibitors that contains the octahydro-2H-chromen-4-ol scaffold
Molecules
23
E2468
2018
Homo sapiens (Q9NUW8)
brenda
Borda, M.A.; Palmitelli, M.; Veron, G.; Gonzalez-Cid, M.; de Campos Nebel, M.
Tyrosyl-DNA-phosphodiesterase I (TDP1) participates in the removal and repair of stabilized-Top2alpha cleavage complexes in human cells
Mutat. Res.
781
37-48
2015
Homo sapiens (Q9NUW8), Homo sapiens
brenda
Cuya, S.M.; Comeaux, E.Q.; Wanzeck, K.; Yoon, K.J.; van Waardenburg, R.C.
Dysregulated human tyrosyl-DNA phosphodiesterase I acts as cellular toxin
Oncotarget
7
86660-86674
2016
Homo sapiens (Q9NUW8), Homo sapiens
brenda
Nale, S.; Jadhav, V.
Synthesis of tyrosyl-DNA phosphodiesterase I inhibitors
Tetrahedron Lett.
57
2652-2654
2016
Homo sapiens (Q9NUW8)
-
brenda